Insight

First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

lymphomahub.com

Dec 7, 2024, 11:15

First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

Guilherme Perini, Hematologist at Hospital Israelita Albert Einstein in São Paulo, shared a post on X:

“First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

Tim Fenske and ECOG-ACRIN EA4151 investigators show that, for patients achieving MRD negativity after modern induction in MCL does not benefit from ASCT.

MRD was done by ClonoSeq, not avaliable in Latam.

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Authors: Timothy S. Fenske, Xin Victoria Wang, Brian G. Till, Kristie A. Blum, Matthew Lunning, Hillard M. Lazarus, Paul A.S. Fishkin, Lale Kostakoglu Shields, David W. Scott, Ann S. LaCasce, Patrick B. Johnston, Amanda F. Cashen, Leslie L. Popplewell, Robert M. Dean, Nausheen Ahmed, , Nirav N. Shah, Nina D. Wagner-Johnston, Boyu Hu, Bhagirathbhai R. Dholaria, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl.

First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

As data from Grupo GELL has shown, less than 40 percent of eligible patients in LatAm go to ASCT in MCL.

ClonoSeq is waycheaper than ASCT, and could help, in $-restricted countries, select patients who really benefit from ASCT…

And that was not the biggest hit in ASCT for MCL…”

Amanda F. Cashen Ann S. LaCasce ASCT Bhagirathbhai R. Dholaria Boyu Hu Brad S. Kahl Brian G. Till cancer clonoSEQ David W. Scott ECOG-ACRIN EA4151 Grupo GELL Guilherme Perini Hillard M. Lazarus John P. Leonard Jonathan W. Friedberg Kristie A. Blum Lale Kostakoglu Shields LATAM Leslie L. Popplewell Matthew Lunning MCL MRD Nausheen Ahmed Nina D. Wagner-Johnston Nirav N. Shah OncoDaily Oncology Patrick B. Johnston Paul A.S. Fishkin Richard F. Little Robert M. Dean Tim Fenske Timothy S. Fenske Xin Victoria Wang

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology